Capital Investment Counsel LLC Sells 2,482 Shares of AbbVie Inc. $ABBV

Capital Investment Counsel LLC trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 4.9% during the third quarter, Holdings Channel.com reports. The institutional investor owned 47,839 shares of the company’s stock after selling 2,482 shares during the quarter. AbbVie accounts for approximately 1.6% of Capital Investment Counsel LLC’s investment portfolio, making the stock its 16th biggest holding. Capital Investment Counsel LLC’s holdings in AbbVie were worth $11,077,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ABBV. Vanguard Group Inc. raised its holdings in shares of AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after purchasing an additional 3,380,842 shares during the period. Geode Capital Management LLC increased its holdings in shares of AbbVie by 2.4% during the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock valued at $7,240,169,000 after acquiring an additional 924,761 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of AbbVie by 6.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after purchasing an additional 1,517,222 shares during the period. Norges Bank acquired a new stake in AbbVie in the 2nd quarter valued at $4,288,200,000. Finally, Raymond James Financial Inc. raised its holdings in AbbVie by 41.8% during the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after buying an additional 2,753,312 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on ABBV shares. Citigroup decreased their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday, January 27th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 target price (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Evercore reduced their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Finally, Guggenheim lifted their price objective on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $251.00.

AbbVie Stock Up 3.0%

ABBV stock opened at $227.57 on Friday. The stock has a 50-day simple moving average of $223.45 and a two-hundred day simple moving average of $220.35. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The firm has a market capitalization of $402.20 billion, a PE ratio of 96.43, a PEG ratio of 0.77 and a beta of 0.35.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same period in the previous year, the business earned $2.16 EPS. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales and upbeat execution: AbbVie reported record net sales and raised forward visibility after Q4 results, with analysts (e.g., Cantor Fitzgerald) reiterating bullish views and a $250 target tied to Skyrizi and Rinvoq strength. AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
• Positive Sentiment: Korean post‑marketing Rinvoq study completed — bolsters real‑world evidence for Rinvoq in immunology, supporting long‑term revenue growth for the immunology franchise. Real‑world data can aid uptake and payer discussions. AbbVie’s Korean Rinvoq Study Wraps Up, Bolstering Real-World Data for Immunology Growth
• Neutral Sentiment: Analyst notes and reports are reframing valuation: recent analyst reports (Argus, other coverage) review AbbVie’s pipeline and valuation after strong results — useful for context but not a consensus catalyst. Analyst Report: AbbVie Inc
• Neutral Sentiment: Pipeline updates (elezanumab phase 2): AbbVie updated a Phase 2 study in acute cervical spinal cord injury — monitor readouts for potential long‑term upside but no immediate revenue impact. AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury
• Neutral Sentiment: Small analyst PT trim from Evercore ISI: Evercore trimmed its price target modestly but kept an Outperform rating — suggests confidence in fundamentals despite nearer‑term headwinds. Evercore ISI Cuts AbbVie Inc. (ABBV) PT
• Negative Sentiment: Legal and policy risk: AbbVie sued HHS/CMS after Botox was selected for Medicare drug price negotiation under the Inflation Reduction Act — outcome could materially affect Botox pricing and margins. This litigation creates near‑term uncertainty. AbbVie sues US health agency over Botox price controls
• Negative Sentiment: Competitive pressure in immunology: J&J’s heavy Tremfya ad spend is intensifying competition for AbbVie’s Rinvoq and Skyrizi, which could pressure market share and growth trajectories in key indications. J&J’s Tremfya roars 2026 ad spend trailed by AbbVie’s Rinvoq and Skyrizi
• Negative Sentiment: U.S. operational changes and Medicaid concessions: AbbVie is reshaping U.S. operations and making Medicaid concessions to manage pricing headwinds — could weigh on near‑term U.S. margins even as it targets long‑term growth. AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.